IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Share this content:
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
 
Sponsors and Collaborators
Immatics Biotechnologies GmbH
 
Contact
Alexandra Kirner, PhD
+49 7071 5397400
kirner@immatics.com

Carsten Reinhardt, MD
+49 7071 5397100
reinhardt@immatics.com
 
Principal Investigators
Brian Rini, MD
Cleveland Clinic Taussig Cancer Institute

Tim Eisen, MD
Addenbrooke's Hospital University of Cambridge, UK
 
ClinicalTrials.gov Identifier
NCT01265901

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs